34916-10-4 Usage
Description
Cyclohexanecarbonitrile, 4-oxo-, also known as 4-Cyanocyclohexanone, is an organic compound with the molecular formula C7H9NO. It is a key intermediate in the synthesis of various pharmaceuticals and chemicals due to its unique structure and reactivity.
Uses
Used in Pharmaceutical Industry:
Cyclohexanecarbonitrile, 4-oxois used as a key intermediate for the preparation of nicotinamides, which serve as phosphodiesterase 4 (PDE4) D isoenzyme inhibitors. These inhibitors play a crucial role in treating various inflammatory and autoimmune diseases by modulating the immune response and reducing inflammation.
Additionally, Cyclohexanecarbonitrile, 4-oxois used as an anthranilic acid replacement in the synthesis of niacin receptor agonists. These agonists are important for the treatment of various conditions, including hypercholesterolemia, atherosclerosis, and other cardiovascular diseases, as they help regulate lipid metabolism and improve overall cardiovascular health.
Check Digit Verification of cas no
The CAS Registry Mumber 34916-10-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,9,1 and 6 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 34916-10:
(7*3)+(6*4)+(5*9)+(4*1)+(3*6)+(2*1)+(1*0)=114
114 % 10 = 4
So 34916-10-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H9NO/c8-5-6-1-3-7(9)4-2-6/h6H,1-4H2
34916-10-4Relevant articles and documents
Direct C(sp3)-H Cyanation Enabled by a Highly Active Decatungstate Photocatalyst
Kim, Kunsoon,Lee, Seulchan,Hong, Soon Hyeok
supporting information, p. 5501 - 5505 (2021/07/26)
A highly efficient, direct C(sp3)-H cyanation was developed under mild photocatalytic conditions. The method enabled the direct cyanation of various C(sp3)-H substrates with excellent functional group tolerance. Notably, complex natural products and bioactive compounds were efficiently cyanated.
NOVEL COMPOUNDS FOR USE IN CANCER
-
Page/Page column 46; 47, (2019/01/07)
It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures of stereoisomers, wherein X, L,R1, R 2, and R 3 are as defined herein, which are cancer cell differentiation inducing agents. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, in particular by cell differentiation therapy.
QUINOLINE DERIVATIVES AS SMO INHIBITORS
-
Paragraph 0211; 0213, (2017/02/28)
Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.
